![James Porter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 36 M $ al 31/05/2026
James R.
Porter is President, Chief Executive Officer & Director at Nuvalent, Inc. since 2020, with employment at the company starting in 2017.
Formerly, Dr. Porter was Vice President-Product Development at Infinity Pharmaceuticals, Inc. from 2002 to 2016.
Education includes a doctorate from Boston College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NUVALENT, INC. CLASS A 0,44 % | 08/06/2026 | 324.879 ( 0,44 % ) | 36 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NUVALENT, INC. | Director Ejecutivo | 01/01/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2016 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
